Psychiatry

Your daily dose of the clinical news you may have missed.

Suicide prevention falls squarely in the purview of primary care practitioners, says family physician Teresa Lovins, MD. She reviews an intervention with remarkable results.

Your daily dose of the clinical news you may have missed.

ACP 2025: Matthew Press, MD, shares actionable steps for primary care physicians to adopt a collaborative care model, including how to start small and partner with other practices.

ACP 2025: Dr Press discusses how the Penn Integrated Care model equips primary care physicians to manage mental health conditions more effectively while reducing burnout.

ACP 2025: Discover how the collaborative care model supports mental health in primary care through team-based care, symptom tracking, and psychiatric consultation—boosting outcomes and reducing burden on clinicians.

In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.

In the pediatric population aged 0 to 19 years, exposure to fentanyl was through intentional use by two-thirds, investigators found.

More than one-third of study participants with TRD had failed to get relief from 4 or more antidepressants, calling treatment experiences a "trial and error" process.

Axsome Therapeutics reported that the FDA feedback supports the company's regulatory package for a sNDA for the dextromethorphan/bupropion combination.

Patients with depression from high-wealth areas were 1.62 times more likely in primary care and 1.67 times more likely in psychiatry to use telehealth.

The FDA accepted the sNDA for risperidone (Uzedy) extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.

Comorbid conditions accrued at a rate 30% faster among adults with depression than in those without the disorder over a 7-year follow-up period.

People with MDD demonstrated a preference for carbohydrate-rich foods and reduced reward from fat- and protein-rich foods, according to new research.

The first patient was dosed in the Panorama study assessing MM120 ODT, a form of LSD, for the treatment of GAD.

GH001, an inhalable 5-MeO-DMT therapy, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

Brexpiprazole and sertraline showed promise for PTSD treatment in a recent study. Lead author, Lori Davis, MD, discusses clinical findings, treatment guidelines, and future research directions.

Your daily dose of the clinical news you may have missed.

Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.

The investigational and potentially first-in-class therapy may enhance AMPA receptor sensitivity to glutamate, enhancing neuronal transmission.

Findings on the efficacy of treatments for MDD include the favorable effects of exercise, of CBT, and the robust outcomes of ECT among neuromodulatory modalities.

The approval of esketamine follows an FDA Priority Review and is based on data showing that esketamine alone demonstrated rapid and superior improvement in depressive symptoms compared with placebo.

Your daily dose of the clinical news you may have missed.

A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.

The acquisition brings lumateperone, known as Caplyta, and the clinical-stage agent ITI-1284, for generalized anxiety disorder and Alzheimer's agitation, into the J&J fold.

Your daily dose of the clinical news you may have missed.

An earlier phase 2 study found statistically significant improvement of MDD in female participants.

The adcomm meeting is expected to happen in the first half of 2025, and means the FDA expects to miss the target PDUFA date.

The failure of the novel kappa opioid receptor antagonist to best placebo in the first of triplicate phase 3 studies has Neumora concerned but not deterred.